Drug intelligence / Profile preview

magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone

Development stage: Unknown
Lead developer: Lo.Li. Pharma
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
Administration: Oral, Vaginal

Overview

This combination therapy is an investigational regimen being studied by the University of Roma La Sapienza for the prevention of preterm birth in women with a short cervix. It consists of a daily oral supplement containing magnesium (450 mg), palmitoylethanolamide (200 mg), high-molecular-weight hyaluronic acid (200 mg), vitamin B6 (2.6 mg), and vitamin D (2000 IU), administered alongside the standard-of-care vaginal progesterone (200 mg). The treatment aims to reduce the incidence of preterm delivery by leveraging the synergistic effects of its components: progesterone maintains uterine quiescence; magnesium acts as a tocolytic; palmitoylethanolamide (PEA) provides anti-inflammatory effects via PPAR-alpha activation; high-molecular-weight hyaluronic acid (HMWHA) offers structural support and anti-inflammatory properties; and vitamins B6 and D support maternal-fetal immune and metabolic health.

Other names: Magnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PR (Progesterone receptor)PGRMC1VDR (Vitamin D receptor)CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on magnesium + palmitoylethanolamide + high molecular weight hyaluronic acid + vitamin B6 + vitamin D + progesterone.